An oral non-peptide small-molecule GLP-1 receptor agonist from Eli Lilly, taken once daily as a pill, with large late-stage obesity and diabetes trials behind it.
Reviewed for accuracy · Last reviewed July 8, 2026Orforglipron (LY3502970) is a small molecule, not a peptide. Unlike the injectable incretin peptides elsewhere on this site, it is a once-daily oral GLP-1 receptor agonist, which is why it can be taken as a pill rather than reconstituted and injected. It is included here as an adjacent oral metabolic compound.
It carries large Phase 2 and Phase 3 data (the ATTAIN obesity program and the ACHIEVE diabetes program), and because it is a small molecule taken orally, trials reported it can be taken without food or water restrictions. As of 2026 its regulatory status was moving quickly: Eli Lilly reported filing it with the FDA, so it may be under review or newly authorized. Check a current, authoritative source for its exact approval status rather than relying on this page for that detail.
Trials used once-daily oral doses: 12 – 45 mg in the Phase 2 obesity trial, 6/12/36 mg in Phase 3 obesity (ATTAIN-1), and 3/12/36 mg in Phase 3 diabetes (ACHIEVE-1), each reached through gradual escalation. As an oral tablet there is no reconstitution or syringe conversion.
Read the full Orforglipron dosage guide →Across trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), generally mild to moderate and concentrated during dose escalation, consistent with other GLP-1 receptor agonists.
Read the full Orforglipron side effects guide →As an oral tablet, orforglipron does not need refrigeration or reconstitution, and trials noted no food or water timing restrictions. Store tablets at room temperature per the product label. See the full storage & safety guide for general handling basics.
This page is an independent educational reference and is not medical advice. Talk to a doctor before starting or adjusting any compound.